English / Deutsch
Corporate Portrait
(according to guidelines of the Open Market at the Frankfurt Stock Exchange)
Statement Of Trading Data
|
Number Of Outstanding Shares |
|
4,487,800 |
|
|
Capital Stock |
|
€ 4,487,800.00 |
|
|
Free Float |
|
42.21% |
|
|
Shareholder Structure |
|
Family Wagner |
17.76% |
|
|
Family Wolf |
17.33% |
|
|
|
Family Ehl |
2.90% |
|
|
|
S-Refit AG |
11.63% |
|
|
|
EquiNet EarlyStage Capital Fonds Nr. 1 GmbH & Co. KG |
8.17% |
|
|
|
Free Float |
42.21% |
|
|
Lead Broker |
Fa. Fleischhacker, Frankfurt a.M. |
||
|
Applicant |
WestLB AG, Düsseldorf |
||
|
German Stock Exchange Listing Partner |
|
WestLB AG, Düsseldorf |
|
|
Designated Sponsor |
|
WestLB AG, Düsseldorf |
|
Corporate Information
|
Date Of Foundation |
GENEART AG was founded on February 21, 2006 and entered in the Commercial Register on March 20, 2006.
The predecessor company GENEART GmbH was founded on November 5, 1999 and entered in the Commercial Register on December 7, 1999. |
||
|
Accounting Standard |
HGB |
||
|
Fiscal Year-End |
31. Dezember |
||
|
Names And Functions Of The Management Board And Supervisory Board Members |
Management Board |
|
|
|
Prof. Dr. Ralf Wagner, CEO, CSO |
|||
|
Christian Ehl, CEO, CFO |
|
||
|
Supervisory Board |
|||
|
Dr. Farsin Yadegardjam, |
|||
|
Bertram Gilka-Bötzow, |
|
||
|
Prof. Dr. Hans Wolf |
|||
Business Description at a glance
GENEART AG is in the DNA engineering and processing business since 2000. DNA engineering and processing stands for developments and services that allow gene sequences to be selectively manipulated, redesigned, and reassembled according to rational requirements, and to be produced in larger quantities for various applications, including drug development. GENEART’s services portfolio ranges from the production of optimized synthetic genes, the generation of gene variants and gene libraries to the production of DNA-based active agents.
GENEART’s core business is gene synthesis. In addition, GENEART also offers other services that are closely related to gene synthesis. These services cater to the ever-growing need for rationally designed gene variants and customized gene libraries (combinatorial biology), which are delivered preferentially in the customer-preferred plasmid vectors (Plasmid Services). The corresponding services are combined within the business areas of Gene Evolution (combinatorial biology) and Gene Delivery (Plasmid Services).
By using synthetic genes, gene variants as well as gene libraries, the development and production of modern drugs and bioproducts can be significantly improved and accelerated. Meanwhile, GENEART’s designed and produced genes are used by numerous pharmaceutical and chemical companies, biotechnology companies, as well as various universities and large research institutions to develop and manufacture new therapeutics and vaccines as well as to identify and produce improved industrial enzymes.
Print